BACKGROUND: @entity413 control is mandatory in pregnant @entity1 with @entity164 1 @entity6 to keep the incidence of @entity600 and complications low. Insulin Lispro is a new and popular fast-acting insulin analog used for intensified insulin therapy. Although popular among young @entity1 , this drug has not been licensed for use in pregnancy due to a possibly increased risk of fetal @entity600 . CASE REPORT: Retrospectively, the case of a 34-year-old @entity1 with @entity1723 , gravid III and para III, which carried her second and third @entity1 full time under Lispro treatment, was analyzed. We performed an interview of the @entity1 and her doctors. Additionally, the pregnancy documents along with the examination documents of the @entity1 , our @entity1 files, and the blood @entity413 documentation were investigated. Contrary to the first pregnancy which was carried out in the absence of Lispro (first degree @entity572 ), both subsequent pregnancies were completely normal despite continuous Lispro therapy. HbA(1c) values in the range of 4.9-5.9% showed an adequate @entity413 control throughout these pregnancies. CONCLUSION: This case supports the hypothesis that insulin Lispro which is highly popular among young @entity1 can safely and effectively be used in pregnancies. In order to be able to adequately assess possible risks associated with this application, additional cases need to be documented and analyzed.

[Two consecutive pregnancies in a XXXX 1 diabetic under treatment with insulin Lispro].

@entity1 :: ('9606', 'Species') :: ['women', 'children', 'woman', 'patients', 'patient', 'child'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity600 :: ('MESH:D000014', 'Disease') :: ['malformations'] @entity1723 :: ('MESH:D003922', 'Disease') :: ['diabetes type 1'] @entity572 :: ('MESH:D006617', 'Disease') :: ['hip dysplasia'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose', 'Glucose']
@entity164 :: (MESH:D017827,Disease) :: ['type']
